Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
——
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
——
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
——

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's available for sale securities debt securities current?
Arcus Biosciences (RCUS) reported available for sale securities debt securities current of $621M in Q1 2026.
How has Arcus Biosciences's available for sale securities debt securities current changed year-over-year?
Arcus Biosciences's available for sale securities debt securities current decreased by 22.9% year-over-year, from $805M to $621M.
What is the long-term trend for Arcus Biosciences's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Arcus Biosciences's available for sale securities debt securities current has grown at a 6.5% compound annual growth rate (CAGR), from $555.23M to $759M.